TABLE 7

Mean (±SE) neurogenic (autonomic) symptom scores during hyperinsulinemic stepped hypoglycemic clamps on the morning and, after an additional 2 h of hypoglycemia (50 mg/dl), the afternoon of day 1 and on the morning of day 2 in nondiabetic subjects (n = 15) and patients with type 2 diabetes treated with OHA (n = 7) or insulin (n = 6)

Time (min)
P
−30−150306090120150180210240270300
Nondiabetic subjects
 Day 12.3 ± 0.62.2 ± 0.52.7 ± 0.62.6 ± 0.53.2 ± 0.63.0 ± 0.63.3 ± 0.73.7 ± 0.74.0 ± 0.74.9 ± 0.96.6 ± 1.09.5 ± 1.713.1 ± 2.0
 Day 21.7 ± 0.51.5 ± 0.52.1 ± 0.62.2 ± 0.62.5 ± 0.62.6 ± 0.62.8 ± 0.63.7 ± 0.83.5 ± 0.64.7 ± 0.96.3 ± 4.17.3 ± 1.210.5 ± 1.40.1488
Type 2 diabetic patients
 OHA Rx*
  Day 12.3 ± 0.21.6 ± 0.62.3 ± 0.92.7 ± 1.12.1 ± 0.82.9 ± 1.33.5 ± 1.57.9 ± 4.111.0 ± 3.14.1 ± 4.17.6 ± 5.18.7 ± 4.220.5 ± 5.0
  Day 21.7 ± 1.01.7 ± 1.01.8 ± 1.02.0 ± 0.92.5 ± 0.93.0 ± 0.92.7 ± 1.13.3 ± 0.94.5 ± 0.94.5 ± 1.28.5 ± 1.712.8 ± 3.216.0 ± 4.30.0306
 Insulin Rx*
  Day 12.0 ± 2.02.5 ± 0.92.8 ± 1.03.0 ± 0.92.7 ± 0.72.7 ± 0.82.8 ± 0.83.8 ± 0.64.0 ± 0.85.3 ± 1.39.0 ± 2.010.5 ± 2.521.0 ± 3.4
  Day 21.0 ± 1.01.0 ± 1.00.6 ± 0.60.6 ± 0.61.4 ± 1.01.8 ± 1.01.8 ± 1.02.2 ± 1.02.6 ± 1.13.0 ± 1.37.4 ± 2.210.8 ± 4.913.0 ± 4.90.0202
  • *

    * Type 2 diabetic (n = 13) P = 0.0149 day 2 versus day 1;

  • day 1 P = 0.0023 versus nondiabetic.